Insider Transactions in Q1 2025 at Revance Therapeutics, Inc. (RVNC)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 06
2025
|
Julian S Gangolli |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Carey O Connor Kolaja |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Olivia C Ware |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Erica Jordan Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
107,942
-100.0%
|
-
|
|
Feb 06
2025
|
David Hollander CMO & Global Therapeutics Lead |
SELL
Sale (or disposition) back to the issuer
|
Direct |
95,212
-100.0%
|
-
|
|
Feb 06
2025
|
Dwight Moxie CLO & GC |
SELL
Sale (or disposition) back to the issuer
|
Direct |
114,104
-100.0%
|
-
|
|
Feb 06
2025
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
18,125
+50.0%
|
-
|
|
Feb 06
2025
|
Tobin Schilke CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
124,438
-100.0%
|
-
|
|
Feb 06
2025
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
20,883
+50.0%
|
-
|
|
Feb 06
2025
|
Mark J Foley President & CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
112,619
-100.0%
|
-
|
|
Feb 06
2025
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
84,686
+50.0%
|
-
|
|
Feb 06
2025
|
Angus C. Russell |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Chris Nolet |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Jill Beraud |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 06
2025
|
Vlad Coric |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,000
-100.0%
|
-
|
|
Feb 04
2025
|
Julian S Gangolli |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
30,106
-66.75%
|
$90,318
$3.65 P/Share
|
|
Feb 04
2025
|
Carey O Connor Kolaja |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,561
-52.47%
|
$49,683
$3.65 P/Share
|
|
Feb 04
2025
|
Olivia C Ware |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
16,675
-52.64%
|
$50,025
$3.65 P/Share
|
|
Feb 04
2025
|
Erica Jordan Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,922
-6.03%
|
$20,766
$3.65 P/Share
|
|
Feb 04
2025
|
David Hollander CMO & Global Therapeutics Lead |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,733
-9.27%
|
$29,199
$3.65 P/Share
|
|
Feb 04
2025
|
Dwight Moxie CLO & GC |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
47,815
-33.25%
|
$143,445
$3.65 P/Share
|
|
Feb 04
2025
|
Tobin Schilke CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
97,999
-48.62%
|
$293,997
$3.65 P/Share
|
|
Feb 04
2025
|
Mark J Foley President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
110,913
-100.0%
|
$332,739
$3.65 P/Share
|
|
Feb 04
2025
|
Mark J Foley President & CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
996,935
-97.27%
|
$2,990,805
$3.65 P/Share
|
|
Feb 04
2025
|
Angus C. Russell |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
36,506
-70.88%
|
$109,518
$3.65 P/Share
|
|
Feb 04
2025
|
Chris Nolet |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
28,606
-65.6%
|
$85,818
$3.65 P/Share
|
|
Feb 04
2025
|
Jill Beraud |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
28,606
-65.6%
|
$85,818
$3.65 P/Share
|
|
Feb 04
2025
|
Vlad Coric |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
5,784
-27.83%
|
$17,352
$3.65 P/Share
|
|
Feb 03
2025
|
Dwight Moxie CLO & GC |
BUY
Grant, award, or other acquisition
|
Direct |
5,979
+3.99%
|
-
|
|
Feb 03
2025
|
Tobin Schilke CFO |
BUY
Grant, award, or other acquisition
|
Direct |
6,888
+3.3%
|
-
|
|
Feb 03
2025
|
Mark J Foley President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
27,933
+2.65%
|
-
|